secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001157523-23-000411
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports FY 2022 LIVMARLI net product sales of $75.1M; Q4 sales up 48% QoQ
-------------------------------------------------------------------------------

- Full year 2022 LIVMARLI net product sales $75.1M (vs $3.1M in 2021); total revenue $77.1M.
- Q4 2022 net sales up 48% vs Q3 2022; U.S. business guided for 50% growth in 2023.
- Operating expenses $208.3M for 2022 (up from $192.6M in 2021); cash & investments $251.7M.
- sNDA submitted for LIVMARLI in PFIC; data milestones in biliary atresia (H2 2023) and volixibat programs.
- Capital raises net $121.9M since Jan 2022; net royalty obligations reduced via Satiogen acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/0001157523-23-000411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/a53358541.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer